NIH/INDUSTRY PRICING FORMULA AGREEMENT MAY BE PREREQUISITE TO CRADA PRODUCT LAUNCH UNDER REVISED WYDEN BILL; PASSAGE THIS YEAR NOT LIKELY, AIDE SAYS
Executive Summary
An agreement with the National Institutes of Health on pricing would be a prerequisite for a company to launch a product developed through a Cooperative Research & Development Agreement with NIH under a revised version of CRADA legislation being developed by Rep. Wyden (D-Ore.), Wyden Chief Health Policy Advisor David Schulke told the Drug Information Association annual meeting June 8.